Experimental drug shows promise against tough cancers

NCT ID NCT05119907

First seen Nov 17, 2025 · Last updated May 15, 2026 · Updated 18 times

Summary

This study tests how well the drug sacituzumab govitecan works in people with advanced solid tumors that have not responded to other treatments. About 53 adults with certain types of esophageal or stomach cancer will receive the drug. The main goal is to see if tumors shrink or disappear.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Anhui Provincial Hospital

    Hefei, 230001, China

  • Beijing Cancer Hospital

    Beijing, 100142, China

  • Beijing Obstetrics and Gynecology Hospital, Capital Medical University

    Beijing, 100006, China

  • Chinese Academy of Medical Sciences Cancer Hospital

    Beijing, 100021, China

  • Fujian Cancer Hospital

    Fuzhou, 350014, China

  • Harbin Medical University Cancer Hospital

    Harbin, 150076, China

  • Henan Cancer Hospital

    Zhengzhou, 450000, China

  • Jiangsu Province Hospital

    Nanjing, 210029, China

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, 310003, China

  • The First Hospital of Jilin University

    Changchun, 130021, China

  • The Sixth Affiliated Hospital, Sun Yat-Sen University

    Guangzhou, 510655, China

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, 43006, China

  • Zhejiang Cancer Hospital

    Hangzhou, 310022, China

Conditions

Explore the condition pages connected to this study.